Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Oncogenes and thyroid tumors].

Ludovic Lacroix1, Jean Charles Soria, Jean Michel Bidart

  • 1Institut Gustave-Roussy, 94805 Villejuif Cedex.

Bulletin Du Cancer
|February 4, 2005
PubMed
Summary

Genetic mutations in thyroid cancer are common. Papillary thyroid carcinomas often have RET/PTC rearrangements or BRAF/RAS mutations, while follicular carcinomas show RAS mutations or PAX8-PPARgamma rearrangements. Anaplastic thyroid carcinomas feature p53 gene mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Circulating tumour DNA in patients with colorectal cancer undergoing curative-intent LIver MEtastases Surgery in France: a prospective, multicentre GERCOR G-118 CLIMES PRODIGE 77 cohort study protocol.

BMJ open·2026
Same author

A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.

Cancer discovery·2026
Same author

Tumor Purity as a Prognostic and Predictive Biomarker of Postoperative Radiation Therapy Outcomes in Stage IIIA-N2 Non-Small Cell Lung Cancer: A Transcriptomic Analysis From the Lung ART Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Genetic variant interpretation in tumours in the French national ring trials Gen&Tiss - main criteria of improvement.

Virchows Archiv : an international journal of pathology·2026
Same author

Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Thyroid carcinomas are the most common endocrine malignancies.
  • Understanding the genetic drivers of different thyroid carcinoma subtypes is crucial for diagnosis and treatment.
  • Specific genetic alterations are associated with distinct histological types of thyroid cancer.

Purpose of the Study:

  • To identify and characterize the key genetic alterations present in major thyroid carcinoma subtypes.
  • To correlate specific gene mutations and rearrangements with papillary, follicular, and anaplastic thyroid carcinomas.
  • To elucidate the role of genetic mutations in the pathogenesis of thyroid cancer.

Main Methods:

  • Analysis of genetic mutations and rearrangements in thyroid carcinoma tissues.

Related Experiment Videos

  • Utilizing molecular techniques to detect specific gene alterations (e.g., RET/PTC, RAS, BRAF, PAX8-PPARgamma, p53).
  • Correlation of molecular findings with histopathological classification of thyroid tumors.

    • Main Results:

    • Papillary thyroid carcinomas (70% of cases) exhibit RET/PTC rearrangements or activating mutations in BRAF or RAS genes, leading to MAP kinase pathway activation.
    • Follicular carcinomas are associated with RAS mutations or PAX8-PPARgamma rearrangements.
    • Inactivating mutations of the p53 gene are exclusively identified in anaplastic thyroid carcinomas.

    Conclusions:

    • Distinct genetic profiles characterize different subtypes of thyroid carcinoma.
    • Specific molecular alterations serve as diagnostic markers for papillary, follicular, and anaplastic thyroid cancers.
    • Targeting specific pathways activated by these mutations may offer therapeutic strategies for thyroid cancer.